<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Carbinoxamine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00748</strong>&#160; (APRD00765)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state &#8220;do not use&#8221; in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00748/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00748/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00748.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00748.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00748.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00748.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00748.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00748">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Carbinoxamin</td><td>German</td><td>INN</td></tr><tr><td>Carbinoxamina</td><td>Spanish</td><td>INN</td></tr><tr><td>Carbinoxamine</td><td>French</td><td>INN</td></tr><tr><td>Carbinoxaminum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Carbinoxamine Maleate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000963/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000963/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000963">DBSALT000963</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Allergefon</td><td>SERP</td></tr><tr><td>Arbinoxa</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Clistin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Histin</td><td>Kenyaku</td></tr><tr><td>Karbinal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Palgic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rotoxamine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Satinmin</td><td>Shou Chan</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Anpirin</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Aseptobron C</td><td>Carbinoxamine and Oxeladin</td></tr><tr><td>Became</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Bimining</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Binin</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Carmine</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Fubinin</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Kenantist </td><td>Carbinoxamine and Triamcinolone</td></tr><tr><td>Kezintea</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Kompimin</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Londec</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Lontec</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Nasalcon</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Nasco</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Pseudo-Carb</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Psubity</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Rhinar</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Rhinohist</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Rhinomode Pediatric</td><td>Carbinoxamine and Phenylephrine</td></tr><tr><td>Rhinopront</td><td>Carbinoxamine and Phenylephrine</td></tr><tr><td>Rotec</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Seuphenon</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Subilin</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Tai Chi</td><td>Carbinoxamine and Pseudoephedrine</td></tr><tr><td>Welimin</td><td>Carbinoxamine and Pseudoephedrine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/histamine-h1-antagonists">Histamine H1 Antagonists</a></li>
<li><a href="/mesh/histamine-antagonists">Histamine Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>486-16-8</td></tr><tr><th>Weight</th><td>Average: 290.788<br>Monoisotopic: 290.118590947</td></tr><tr><th>Chemical Formula</th><td>C<sub>16</sub>H<sub>19</sub>ClN<sub>2</sub>O</td></tr><tr><th>InChI Key</th><td>OJFSXZCBGQGRNV-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">{2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]ethyl}dimethylamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C)CCOC(C1=CC=C(Cl)C=C1)C1=CC=CC=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzylethers</td></tr><tr><th>Direct parent</th><td>Benzylethers</td></tr><tr><th>Alternative parents</th><td>Chlorobenzenes; Pyridines and Derivatives; Aryl Chlorides; Tertiary Amines; Dialkyl Ethers; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; aryl chloride; aryl halide; pyridine; tertiary amine; polyamine; dialkyl ether; ether; organochloride; organohalogen; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.</td></tr><tr><th>Pharmacodynamics</th><td>Carbinoxamine is a first generation antihistamine of the ethanolamine class. Ethanolamine antihistamines have significant antimuscarinic activity and produce marked sedation in most patients. In addition to the usual allergic symptoms, the drug also treats irritant cough and nausea, vomiting, and vertigo associated with motion sickness. It also is used commonly to treat drug-induced extrapyramidal symptoms as well as to treat mild cases of Parkinson's disease. Rather than preventing the release of histamine, as do cromolyn and nedocromil, carbinoxamine competes with free histamine for binding at HA-receptor sites. Carbinoxamine competitively antagonizes the effects of histamine on HA-receptors in the GI tract, uterus, large blood vessels, and bronchial muscle. Ethanolamine derivatives have greater anticholinergic activity than do other antihistamines, which probably accounts for the antidyskinetic action of carbinoxamine.</td></tr><tr><th>Mechanism of action</th><td>Carbinoxamine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Carbinoxamine's anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>10 to 20 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9787</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.955</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.7503</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6804</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5997</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.7956</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8203</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5558</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6473</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8452</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8403</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5557</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8751
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9182
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.9003 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7085
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6835
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Mcneil pharmaceutical co div mcneilab inc</li>
<li>Boca pharmacal inc</li>
<li>Cypress pharmaceutical inc</li>
<li>Mikart inc</li>
<li>Invagen pharmaceuticals inc</li>
<li>Ortho mcneil pharmaceutical inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.bocapharmacal.com">Boca Pharmacal</a></li>
<li><a href="http://www.bpirx.com">Breckenridge Pharmaceuticals</a></li>
<li><a href="http://greatsouthernlabs.com">Great Southern Laboratories</a></li>
<li><a href="http://www.mikart.com">Mikart Inc.</a></li>
<li><a href="http://www.pamlab.com">Pamlab LLC</a></li>
<li>Pan American</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Scientific Laboratories Inc.</li>
<li><a href="http://www.sovpharm.com">Sovereign Pharmaceuticals Ltd.</a></li>
<li>Teamm Pharmaceuticals Inc.</li>
<li><a href="http://trimedlabs.com">Tri Med Laboratories Inc.</a></li>
<li><a href="http://www.zerxis.com">Zerxis Pharmaceuticals</a></li>
<li>Zyber Pharmaceuticals</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution / drops</td><td>Oral</td><td></td></tr><tr><td>Syrup</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet, extended release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00895">Benzylpenicilloyl Polylysine</a></td><td>Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects. </td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01278">Pramlintide</a></td><td>Pramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur.</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Carbinoxamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>